Profile - To The Moon

Xiang15

Posts · 11Posts · 11
Following · 0Following · 0
Followers · 0Followers · 0

- Xiang15Xiang15
  ·2021-06-30
  GOOD
  Sorry, this post has been deleted
  2.17K Comment
  1
  Share
  Report
- Xiang15Xiang15
  ·2021-06-23
  GOOD
  Sorry, this post has been deleted
  2.59K 1
  2
  Share
  Report
- Xiang15Xiang15
  ·2021-06-21
  Noted
  Sorry, this post has been deleted
  1.66K Comment
  1
  Share
  Report
- Xiang15Xiang15
  ·2021-06-21
  Okay
  Orphazyme rose more than 6% in premarket trading
  (June 21) Orphazyme rose more than 6% in premarket trading. What happened Shares of Orphazyme, a c
  Orphazyme rose more than 6% in premarket trading
  1.81K Comment
  2
  Share
  Report
- Xiang15Xiang15
  ·2021-06-21
  Well...
  Sorry, this post has been deleted
  2.54K Comment
  1
  Share
  Report
- Xiang15Xiang15
  ·2021-06-19
  Good
  Sorry, this post has been deleted
  2.01K Comment
  2
  Share
  Report
- Xiang15Xiang15
  ·2021-06-18
  Ok
  Sorry, this post has been deleted
  1.79K Comment
  Like
  Share
  Report
- Xiang15Xiang15
  ·2021-04-07
  h9e
  The decline of China's new energy vehicle sector expanded, with Li Auto falling more than 9%
  4月7日，中概新能源车板块跌幅扩大，理想汽车跌超9%，小鹏汽车跌5%，小牛电动跌超3%，蔚来汽车跌2.6%。
  The decline of China's new energy vehicle sector expanded, with Li Auto falling more than 9%
  1.71K Comment
  Like
  Share
  Report
- Xiang15Xiang15
  ·2021-03-21
  OK
  U.S. Treasury Bond yield surge intensifies, will the Fed "submit"?
  英国媒体周六报道称，美联储正陷入与市场的“摊牌”中。英国《金融时报》称，尽管鲍威尔对美国国债的收益率采取了放任不管的方法，但与他在欧元区的同行相比，投资者仍在质疑美联储可以允许这种利率运行多长时间。美国国债被抛售反映出通胀和增长预期大幅提升，经济学家怀疑美联储最终将被迫提出首次加息。
  U.S. Treasury Bond yield surge intensifies, will the Fed "submit"?
  1.91K Comment
  Like
  Share
  Report
No following yet

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3570852225641368","uuid":"3570852225641368","gmtCreate":1609497474830,"gmtModify":1617846982838,"name":"Xiang15","pinyin":"xiang15","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/256e0a9b35937dcf16d0dca2a61c0c71","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":7,"tweetSize":11,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.02.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":151933808,"gmtCreate":1625061170204,"gmtModify":1703735120814,"author":{"id":"3570852225641368","authorId":"3570852225641368","name":"Xiang15","avatar":"https://static.tigerbbs.com/256e0a9b35937dcf16d0dca2a61c0c71","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570852225641368","idStr":"3570852225641368"},"themes":[],"htmlText":"GOOD","listText":"GOOD","text":"GOOD","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/151933808","repostId":"1195094821","repostType":4,"isVote":1,"tweetType":1,"viewCount":2174,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121083617,"gmtCreate":1624444309839,"gmtModify":1703836855760,"author":{"id":"3570852225641368","authorId":"3570852225641368","name":"Xiang15","avatar":"https://static.tigerbbs.com/256e0a9b35937dcf16d0dca2a61c0c71","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570852225641368","idStr":"3570852225641368"},"themes":[],"htmlText":"GOOD","listText":"GOOD","text":"GOOD","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/121083617","repostId":"2145066064","repostType":4,"isVote":1,"tweetType":1,"viewCount":2589,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167257548,"gmtCreate":1624273317684,"gmtModify":1703832105974,"author":{"id":"3570852225641368","authorId":"3570852225641368","name":"Xiang15","avatar":"https://static.tigerbbs.com/256e0a9b35937dcf16d0dca2a61c0c71","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570852225641368","idStr":"3570852225641368"},"themes":[],"htmlText":"Noted","listText":"Noted","text":"Noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/167257548","repostId":"1153139723","repostType":4,"isVote":1,"tweetType":1,"viewCount":1655,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167254590,"gmtCreate":1624273283510,"gmtModify":1703832104829,"author":{"id":"3570852225641368","authorId":"3570852225641368","name":"Xiang15","avatar":"https://static.tigerbbs.com/256e0a9b35937dcf16d0dca2a61c0c71","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570852225641368","idStr":"3570852225641368"},"themes":[],"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/167254590","repostId":"1184501396","repostType":4,"repost":{"id":"1184501396","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624267024,"share":"https://ttm.financial/m/news/1184501396?lang=en_US&edition=fundamental","pubTime":"2021-06-21 17:17","market":"us","language":"en","title":"Orphazyme rose more than 6% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1184501396","media":"Tiger Newspress","summary":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a c","content":"<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme rose more than 6% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme rose more than 6% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-21 17:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184501396","content_text":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.\nSo what\nThe FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.\nInstead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.\nMany institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.\nNow what\nAccording to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.\nSome shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.\nDespite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"tweetType":1,"viewCount":1812,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167252477,"gmtCreate":1624273200899,"gmtModify":1703832101076,"author":{"id":"3570852225641368","authorId":"3570852225641368","name":"Xiang15","avatar":"https://static.tigerbbs.com/256e0a9b35937dcf16d0dca2a61c0c71","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570852225641368","idStr":"3570852225641368"},"themes":[],"htmlText":"Well...","listText":"Well...","text":"Well...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/167252477","repostId":"1141410103","repostType":4,"isVote":1,"tweetType":1,"viewCount":2539,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":162292496,"gmtCreate":1624063955515,"gmtModify":1703827874730,"author":{"id":"3570852225641368","authorId":"3570852225641368","name":"Xiang15","avatar":"https://static.tigerbbs.com/256e0a9b35937dcf16d0dca2a61c0c71","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570852225641368","idStr":"3570852225641368"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/162292496","repostId":"1138062216","repostType":4,"isVote":1,"tweetType":1,"viewCount":2007,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166549045,"gmtCreate":1624019622887,"gmtModify":1703826704104,"author":{"id":"3570852225641368","authorId":"3570852225641368","name":"Xiang15","avatar":"https://static.tigerbbs.com/256e0a9b35937dcf16d0dca2a61c0c71","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570852225641368","idStr":"3570852225641368"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166549045","repostId":"1133025835","repostType":4,"isVote":1,"tweetType":1,"viewCount":1787,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":341690624,"gmtCreate":1617806112668,"gmtModify":1704703424745,"author":{"id":"3570852225641368","authorId":"3570852225641368","name":"Xiang15","avatar":"https://static.tigerbbs.com/256e0a9b35937dcf16d0dca2a61c0c71","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570852225641368","idStr":"3570852225641368"},"themes":[],"htmlText":"h9e","listText":"h9e","text":"h9e","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/341690624","repostId":"1158255207","repostType":4,"repost":{"id":"1158255207","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1617804748,"share":"https://ttm.financial/m/news/1158255207?lang=en_US&edition=fundamental","pubTime":"2021-04-07 22:12","market":"us","language":"zh","title":"The decline of China's new energy vehicle sector expanded, with Li Auto falling more than 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1158255207","media":"老虎资讯综合","summary":"4月7日，中概新能源车板块跌幅扩大，理想汽车跌超9%，小鹏汽车跌5%，小牛电动跌超3%，蔚来汽车跌2.6%。","content":"<p>On April 7, the decline of China's new energy vehicle sector expanded.<a href=\"https://laohu8.com/S/LI\">Li Auto</a>Fell more than 9%,<a href=\"https://laohu8.com/S/XPEV\">XPeng vehicles</a>Down 5%,<a href=\"https://laohu8.com/S/NIU\">Mavericks Electric</a>It fell more than 3%, and Nio Automobile fell 2.6%.</p><p><img src=\"https://static.tigerbbs.com/1a95c11088139142a4be33ee2dca2ed1\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The decline of China's new energy vehicle sector expanded, with Li Auto falling more than 9%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe decline of China's new energy vehicle sector expanded, with Li Auto falling more than 9%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-04-07 22:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On April 7, the decline of China's new energy vehicle sector expanded.<a href=\"https://laohu8.com/S/LI\">Li Auto</a>Fell more than 9%,<a href=\"https://laohu8.com/S/XPEV\">XPeng vehicles</a>Down 5%,<a href=\"https://laohu8.com/S/NIU\">Mavericks Electric</a>It fell more than 3%, and Nio Automobile fell 2.6%.</p><p><img src=\"https://static.tigerbbs.com/1a95c11088139142a4be33ee2dca2ed1\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/edb5904d62b10798f760277be625646d","relate_stocks":{"LI":"理想汽车","NIO":"蔚来","02015":"理想汽车-W","XPEV":"小鹏汽车"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158255207","content_text":"4月7日，中概新能源车板块跌幅扩大，理想汽车跌超9%，小鹏汽车跌5%，小牛电动跌超3%，蔚来汽车跌2.6%。","news_type":1,"symbols_score_info":{"NIO":0.9,"02015":0.9,"LI":0.9,"XPEV":0.9}},"isVote":1,"tweetType":1,"viewCount":1712,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":359042308,"gmtCreate":1616307780304,"gmtModify":1704792810891,"author":{"id":"3570852225641368","authorId":"3570852225641368","name":"Xiang15","avatar":"https://static.tigerbbs.com/256e0a9b35937dcf16d0dca2a61c0c71","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570852225641368","idStr":"3570852225641368"},"themes":[],"htmlText":"OK","listText":"OK","text":"OK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/359042308","repostId":"2120549145","repostType":4,"repost":{"id":"2120549145","kind":"news","pubTimestamp":1616299535,"share":"https://ttm.financial/m/news/2120549145?lang=en_US&edition=fundamental","pubTime":"2021-03-21 12:05","market":"fut","language":"zh","title":"U.S. Treasury Bond yield surge intensifies, will the Fed \"submit\"?","url":"https://stock-news.laohu8.com/highlight/detail?id=2120549145","media":"FX168","summary":"英国媒体周六报道称，美联储正陷入与市场的“摊牌”中。英国《金融时报》称，尽管鲍威尔对美国国债的收益率采取了放任不管的方法，但与他在欧元区的同行相比，投资者仍在质疑美联储可以允许这种利率运行多长时间。美国国债被抛售反映出通胀和增长预期大幅提升，经济学家怀疑美联储最终将被迫提出首次加息。","content":"<p>British media reported on Saturday (March 20) that the Federal Reserve is locked in a \"showdown\" with the market.</p><p>This week, Federal Reserve Chair Powell acknowledged the rapidly evolving economic outlook and the possibility of further inflation climbing, while underscoring his commitment to keeping interest rates to a minimum for the foreseeable future.</p><p>But this easing approach to inflation is eroding the price of long-term U.S. government bonds, causing ripples in global markets. Despite Powell's laissez-faire approach to yields on US Treasury Bond, investors are still questioning how long the Fed can allow this rate to run compared to his peers in the euro zone, the Financial Times said.</p><p>\"It's not the level of yield that matters, it's the way it interacts with risky assets,\" said Gene Tannuzzo, global head of fixed income at Columbia Threadneedle Investments. \"If yields rise at a rate that causes stocks to fall and credit spreads to widen, then Powell will be more worried.\"</p><p>Over the past week, the benchmark 10-year U.S. Treasury Bond yield jumped to 1.75%, compared to about 1.6% a few days ago. The Bloomberg Barclays index shows that U.S. Treasury Bond prices in the 10-year or longer period have fallen nearly 15% since the beginning of the year. If those losses persist, the first quarter of this year will be the worst sell-off on the U.S. Treasury Bond since at least the early 1970s.</p><p>The sell-off of U.S. Treasury Bond reflects a sharp boost in inflation and growth expectations, and economists suspect that the Federal Reserve will eventually be forced to introduce an initial rate hike.</p><p>Concerned that borrowing costs for companies and individuals could harmfully increase, the ECB has taken steps to counter rising yields in its Treasury Bond. In contrast, the Fed chairman showed no unease, in contrast to March 2020, when policymakers aligned with banks and other market participants about chaotic market movements.</p><p>The swift start of the sell-off to spread to equity and credit markets has angered investors. Treasury Bond yields even topped some of the year's highest expectations after February's poor U.S. Treasury Bond auction, triggering volatile trading.</p><p>Powell on Wednesday again dismissed doubts that he should have concerns about recent volatility in the $2.1 billion U.S. government bond market, reiterating that financials remain \"highly accommodative\" on various indicators, while the central bank will only worry about \"disorderly\" moves that could undermine money markets to support the economic recovery. To illustrate this, he said he had no intention of adjusting the Fed's $120 billion monthly bond-buying program.</p><p>\"The market may force them to change their behavior, but for now Fed policymakers are making it clear that they do not want to be directly involved in behavior that has an impact on the yield curve,\" said Rish Bhandari, senior portfolio manager at hedge funds.</p><p>Mike Collins, senior portfolio manager in PGIM's fixed income division, warned that another big rise in US Treasury Bond yields could test their stance.</p><p>\"It is true that financial conditions are still very easy, but if interest rates rise another half to one percentage point, that does slow down,\" he said. The rally in equity and credit markets may also be severe enough to prompt the Fed to intervene verbally and even shift to measures to buy more long-term debt.</p>","source":"fxdaily_fut","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. Treasury Bond yield surge intensifies, will the Fed \"submit\"?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. Treasury Bond yield surge intensifies, will the Fed \"submit\"?\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">FX168</strong><span class=\"h-time small\">2021-03-21 12:05</span>\n</p>\n</h4>\n</header>\n<article>\n<p>British media reported on Saturday (March 20) that the Federal Reserve is locked in a \"showdown\" with the market.</p><p>This week, Federal Reserve Chair Powell acknowledged the rapidly evolving economic outlook and the possibility of further inflation climbing, while underscoring his commitment to keeping interest rates to a minimum for the foreseeable future.</p><p>But this easing approach to inflation is eroding the price of long-term U.S. government bonds, causing ripples in global markets. Despite Powell's laissez-faire approach to yields on US Treasury Bond, investors are still questioning how long the Fed can allow this rate to run compared to his peers in the euro zone, the Financial Times said.</p><p>\"It's not the level of yield that matters, it's the way it interacts with risky assets,\" said Gene Tannuzzo, global head of fixed income at Columbia Threadneedle Investments. \"If yields rise at a rate that causes stocks to fall and credit spreads to widen, then Powell will be more worried.\"</p><p>Over the past week, the benchmark 10-year U.S. Treasury Bond yield jumped to 1.75%, compared to about 1.6% a few days ago. The Bloomberg Barclays index shows that U.S. Treasury Bond prices in the 10-year or longer period have fallen nearly 15% since the beginning of the year. If those losses persist, the first quarter of this year will be the worst sell-off on the U.S. Treasury Bond since at least the early 1970s.</p><p>The sell-off of U.S. Treasury Bond reflects a sharp boost in inflation and growth expectations, and economists suspect that the Federal Reserve will eventually be forced to introduce an initial rate hike.</p><p>Concerned that borrowing costs for companies and individuals could harmfully increase, the ECB has taken steps to counter rising yields in its Treasury Bond. In contrast, the Fed chairman showed no unease, in contrast to March 2020, when policymakers aligned with banks and other market participants about chaotic market movements.</p><p>The swift start of the sell-off to spread to equity and credit markets has angered investors. Treasury Bond yields even topped some of the year's highest expectations after February's poor U.S. Treasury Bond auction, triggering volatile trading.</p><p>Powell on Wednesday again dismissed doubts that he should have concerns about recent volatility in the $2.1 billion U.S. government bond market, reiterating that financials remain \"highly accommodative\" on various indicators, while the central bank will only worry about \"disorderly\" moves that could undermine money markets to support the economic recovery. To illustrate this, he said he had no intention of adjusting the Fed's $120 billion monthly bond-buying program.</p><p>\"The market may force them to change their behavior, but for now Fed policymakers are making it clear that they do not want to be directly involved in behavior that has an impact on the yield curve,\" said Rish Bhandari, senior portfolio manager at hedge funds.</p><p>Mike Collins, senior portfolio manager in PGIM's fixed income division, warned that another big rise in US Treasury Bond yields could test their stance.</p><p>\"It is true that financial conditions are still very easy, but if interest rates rise another half to one percentage point, that does slow down,\" he said. The rally in equity and credit markets may also be severe enough to prompt the Fed to intervene verbally and even shift to measures to buy more long-term debt.</p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://news.fx168.com/bank/fed/2103/4838373.shtml\">FX168</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/a56aa88d539d7b65b8089a421c05150c","relate_stocks":{"161125":"标普500","513500":"标普500ETF博时","IEF":"债券指数ETF-iShares Barclays 7-10年","IVV":"标普500ETF-iShares","QLD":"2倍做多纳斯达克100指数ETF-ProShares","UPRO":"三倍做多标普500ETF-ProShares","SH":"做空标普500-Proshares","OEF":"标普100指数ETF-iShares","TQQQ":"纳指三倍做多ETF","IEI":"iShares Barclays 3-7 Year Trea","DJX":"1/100道琼斯","SDOW":"三倍做空道指30ETF-ProShares","SQQQ":"纳指三倍做空ETF","OEX":"标普100","TLT":"20+年以上美国国债ETF-iShares","BND":"债券指数ETF-Vanguard美国","DXD":"两倍做空道琼30指数ETF-ProShares","QID":"两倍做空纳斯达克指数ETF-ProShares","SDS":"两倍做空标普500 ETF-ProShares","DDM":"2倍做多道指ETF-ProShares","PSQ":"做空纳斯达克100指数ETF-ProShares","SPXU":"三倍做空标普500ETF-ProShares","GOVT":"iShares安硕核心美国国债ETF","DOG":"道指ETF-ProShares做空",".DJI":"道琼斯","SSO":"2倍做多标普500ETF-ProShares","SHY":"债券指数ETF-iShares Barclays 1-3年国债",".IXIC":"NASDAQ Composite","UDOW":"三倍做多道指30ETF-ProShares","QQQ":"纳指100ETF","SPY":"标普500ETF",".SPX":"S&P 500 Index"},"source_url":"https://news.fx168.com/bank/fed/2103/4838373.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2120549145","content_text":"英国媒体周六（3月20日）报道称，美联储正陷入与市场的“摊牌”中。\n本周，美联储主席鲍威尔承认迅速发展的经济前景以及通货膨胀率进一步攀升的可能，同时强调了他在可预见的未来将利率保持在最低水平的承诺。\n但是，这种对通货膨胀的宽松态度正在侵蚀美国长期政府债券的价格，在全球市场上引发了涟漪。英国《金融时报》称，尽管鲍威尔对美国国债的收益率采取了放任不管的方法，但与他在欧元区的同行相比，投资者仍在质疑美联储可以允许这种利率运行多长时间。\nColumbia Threadneedle Investments全球固定收益负责人Gene Tannuzzo表示：“重要的不是收益率水平，而是其与风险资产之间的相互作用方式。” “如果收益率以导致股市下跌和信贷息差扩大的速度上升，那么鲍威尔将更加担忧。”\n在过去的一周中，基准十年期美国国债收益率跳升至1.75％，几天前约为1.6％。彭博巴克莱（Bloomberg Barclays）指数显示，自今年年初以来，10年或更长期的美国国债价格下跌了近15％。如果这些损失持续下去，那么今年第一季度将是至少自1970年代初以来美国国债遭遇最严重的一次抛售。\n美国国债被抛售反映出通胀和增长预期大幅提升，经济学家怀疑美联储最终将被迫提出首次加息。\n欧洲央行担心公司和个人的借贷成本可能会有害地增加，因此采取措施以抵制其国债收益率的上涨。相比之下，美联储主席表现得并未有任何不安，这与2020年3月的情形形成鲜明对比，当时决策者就混乱的市场走势与银行和其他市场参与者保持一致。\n抛售的迅速开始蔓延到股票和信贷市场，这激怒了投资者。2月份美国国债拍卖表现不佳之后，国债收益率甚至突破了今年最高的一些预期，引发了波动性交易。\n鲍威尔周三再次驳回了应该对21亿美元美国政府债券市场的近期波动担忧的疑虑，重申各种指标的财务状况仍然“高度宽松”，而央行只会担心可能破坏货币市场支持经济复苏的“无序”举动。为说明这一点，他表示无意调整美联储每月1200亿美元的债券购买计划。\n对冲基金高级投资组合经理Rish Bhandari表示：“市场可能会迫使他们改变其行为，但目前美联储决策者明确表示，他们不希望直接参与对收益率曲线产生影响的行为。”\nPGIM固定收益部高级投资组合经理Mike Collins警告说，美国国债收益率的再次大幅上升可能会考验他们的立场。\n他说：“金融状况确实仍然很宽松，但是如果利率再上升0.5至1个百分点，那的确会放慢脚步。”股票和信贷市场的反弹可能也足够严重，以至于促使美联储进行口头干预，甚至转向购买更多长期债务的措施。","news_type":1,"symbols_score_info":{"161125":0.9,"513500":0.9,".DJI":0.9,"OEX":0.9,"QLD":0.9,"TNmain":0.9,"GOVT":0.9,"SSO":0.9,"ZBmain":0.9,"UBmain":0.9,"TQQQ":0.9,"DXD":0.9,"DDM":0.9,"SH":0.9,"IVV":0.9,"SDS":0.9,"ESmain":0.9,"DJX":0.9,"TLT":0.9,"NQmain":0.9,"PSQ":0.9,"SDOW":0.9,"SPY":0.9,"SPXU":0.9,"IEF":0.9,"QID":0.9,"MNQmain":0.9,"UPRO":0.9,"DOG":0.9,"UDOW":0.9,"QQQ":0.9,"OEF":0.9,".SPX":0.9,"BND":0.9,"IEI":0.9,".IXIC":0.9,"SHY":0.9,"ZTmain":0.9,"SQQQ":0.9,"ZFmain":0.9}},"isVote":1,"tweetType":1,"viewCount":1909,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":true}